These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 19460783)

  • 1. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
    Allen GP; Hankins CD
    J Antimicrob Chemother; 2009 Aug; 64(2):359-63. PubMed ID: 19460783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-related selection of fluoroquinolone-resistant Escherichia coli.
    Olofsson SK; Marcusson LL; Strömbäck A; Hughes D; Cars O
    J Antimicrob Chemother; 2007 Oct; 60(4):795-801. PubMed ID: 17635875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the mutant selection window for clindamycin, doxycycline, linezolid, moxifloxacin and trimethoprim/sulfamethoxazole against community-associated meticillin-resistant Staphylococcus aureus (MRSA).
    Allen GP; Deshpande LM
    Int J Antimicrob Agents; 2010 Jan; 35(1):45-9. PubMed ID: 19910164
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Allen GP; Harris KA
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483960
    [No Abstract]   [Full Text] [Related]  

  • 7. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A; Schubert S
    Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
    Firsov AA; Vostrov SN; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
    Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA
    J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
    Allen GP; Deao KM; Hill SA; Schipelliti SM; Tran T
    Int J Antimicrob Agents; 2021 Oct; 58(4):106417. PubMed ID: 34391903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
    Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
    Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
    Kim JM; Kim JS; Kim N; Jung HC; Song IS
    J Antimicrob Chemother; 2005 Nov; 56(5):965-7. PubMed ID: 16159928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
    Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
    Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
    Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
    J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.